Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/39641| Title: | A dose-escalation study of weekly intravenous CRLX301 in patients with advanced solid tumor malignancies. | Authors: | Zamboni W.C.;Gangadhar T.C.;Piha-Paul S.A.;Murphy C.;Senderowicz A.;Wang H.;Markman B.;de Souza P.;Dees E.C. | Monash Health Department(s): | Oncology | Institution: | (Wang) Research, Cerulean Pharma, Inc., Waltham, MA, United States (Markman) Monash Cancer Centre, Monash Health, Melbourne, Australia (de Souza) Medical Oncology, Western Sydney University School of Medicine, Sydney, Australia (Dees) Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, United States (Gangadhar) Hematology-Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, United States (Piha-Paul) Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States (Zamboni) UNC Lineberger Comprehensive Cancer Center, UNC Eshelman School of Pharmacy, Carolina Center for Cancer Nanotechnology Excellence, Chapel Hill, NC, United States (Murphy, Senderowicz) Clinical Operations, Cerulean Pharma, Inc., Waltham, MA, United States | Issue Date: | 26-Mar-2020 | Copyright year: | 2016 | Publisher: | Elsevier Ltd | Place of publication: | United Kingdom | Publication information: | Annals of Oncology. 27 (Supplement 6) (pp vi134), 2016. Date of Publication: 1 October 2016. | Journal: | Annals of Oncology | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1093/annonc/mdw368.56 | ISSN: | 0923-7534 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/39641 | Type: | Article | Subjects: | drug blood level drug dose escalation drug safety drug tolerability human maximum tolerated dose phase 1 clinical trial phase 2 clinical trial priority journal *solid malignant neoplasm/dt [Drug Therapy] *antineoplastic agent/ct [Clinical Trial] *antineoplastic agent/cm [Drug Comparison] *antineoplastic agent/do [Drug Dose] *antineoplastic agent/dt [Drug Therapy] *antineoplastic agent/iv [Intravenous Drug Administration] *antineoplastic agent/pd [Pharmacology] cyclodextrin docetaxel/dt [Drug Therapy] macrogol *nanoparticle *antineoplastic agent/cr [Drug Concentration] antineoplastic activity article advanced cancer drug blood level drug dose escalation drug safety drug tolerability maximum tolerated dose phase 1 phase 2 solid malignant neoplasm antineoplastic agent/ct antineoplastic agent cyclodextrin docetaxel macrogol nanop |antineoplastic activity advanced cancer phase 2 clinical trial priority journal *solid malignant neoplasm / *drug therapy drug tolerability drug safety drug dose escalation maximum tolerated dose human antineoplastic activity advanced cancer phase 1 clinical trial drug blood level Article |
Type of Clinical Study or Trial: | Clinical trial |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.